



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/978,635	11/25/1997	ELAZAR RABBANI	ENZ-53(DIV4)	4641
28171	7590	01/04/2006	EXAMINER	
ENZO BIOCHEM, INC. 527 MADISON AVENUE (9TH FLOOR) NEW YORK, NY 10022			SCHULTZ, JAMES	
		ART UNIT		PAPER NUMBER
		1635		

DATE MAILED: 01/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT PAPER

20051229

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The Petition to Revive an unintentionally abandoned application has been granted. However, numerous Notices of Non--Compliance were subsequently necessitated due to failure to improperly identify the status of subsequent claim amendments. The claim amendment most recently submitted, that of 24 October 2005, is in compliance with 37 CFR 1.121, however it contains claim amendments for which there is no relevant request for reconsideration, and thus is not compliant with 37 CFR 1.111, because it is not indicated why the instantly pending claims are distinctive over the prior art and otherwise in compliance with 35 USC 112. While a request for reconsideration was submitted with the aforementioned Petition to Revive, said request references earlier claim amendments that are no longer present in the instant claims set. For example, the request for reconsideration submitted with the Petition to Revive argues the benefits of non-native introns, which are not claimed anywhere in the instant claims. Correction is required.

J.D. Schultz
J.D. SCHULTZ, Ph.D.
PATENT EXAMINER